Asthmatin 4 stella chewing and treatment of asthma, reducing allergic rhinitis (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Montelukast
Ingredient Stella

Ingredient

Composition information	Content
Montelukast	4mg

Uses

indications

ASTHMATIN drugs are indicated in the following cases:

Long -term treatment and prevention of asthma in adults and children aged 12 months and older. (LTC4, LTD4, LTE4 are products of arachidonic acid metabolism and are released from many different cells, including mast cells and eosinophilia. These eicosanoids are associated with Leukotrien cysteine receptors (CYLT) On other inflammatory cells (including eosinophilia and some marrow stem cells).

CYSLTS is correlated with asthma and allergic rhinitis. In asthma, the indirect effects of Leukotrien include respiratory edema, smooth muscle contraction and transforming cell activity related to inflammatory process.

In allergic rhinitis, CYSLTS is released from the nasal mucosa after the antigen -causing antigen in both early and late phase reactions accompanied by symptoms of allergic rhinitis. The stimulation in the nose caused by CYSLT shows an increase in the resistance of the nose and the symptoms of nasal congestion.

Montelukast is an oral activity associated with CYSLT receptor with high affinity and selection (rather than other important pharmacological receptors in the respiratory tract, such as Prostanoid receptors, cholinergic or beta-adrenergic). Montelukast inhibits the physiological impact of LTD4 at CYSLT1 receptor without any owner activity.

pharmacokinetics

absorption:

Montelukast's peak plasma concentration is achieved after 3-4 hours of medication. The average oral bioavailability is 64%.

Distribution:

Montelukast is connected to plasma proteins over 99%.

Metabolism:

The drug is widely metabolized in the liver thanks to the isoenzyme of Cytochrom P450 are CYP3A4, CYP2A6 and CYP2C9.

Era:

Excretion mainly on feces through bile.

Before taking Asthmatin 4 stella chewing and treatment of asthma, reducing allergic rhinitis (3 blisters x 10 tablets)

How to use

asthmatin should drink once a day.

For asthma, take medicine in the evening. For seasonal allergic rhinitis, the effectiveness of the drug is achieved when taken in the morning or evening does not depend on food.

Time to take medicine to suit the needs of each patient.

Dosage

asthma:

Adults and teenagers aged 15 and older: 1 tablet 10 mg.

Children 6-14 years old: 1 chewing tablet 5 mg.

Children 2-5 years old: 1 tablet chewing 4 mg or 1 pack of nuggets of 4 mg.

Children 12 - 23 months of age: 1 pack of nuggets of 4 mg.

Safety and effectiveness in children under 12 months of age have not been established.

Allergic rhinitis, seasonal allergic rhinitis:

Adults and teenagers aged 15 and older: 1 tablet 10 mg.

Children 6 - 14 years old: 1 chewing tablet 5 mg.

Children 2 - 5 years old: 1 chewing tablet 4 mg or 1 pack of oral pills 4 mg.

Safety and effectiveness in children under 2 years of age with unprocessed seasonal allergic rhinitis.

allergic rhinitis all year round:

Adults and teenagers aged 15 years old: 1 tablet 10 mg.

Children 6 - 14 years old: 1 chewing tablet 5 mg.

Children 2 - 5 years old: 1 chewing tablet 4 mg or 1 pack of oral pills 4 mg.

Children 6 - 23 months old allergic rhinitis year -round: 1 pack of oral nuggets 4 mg.

Safety and effectiveness of treatment in children under 6 months of age with allergic rhinitis all year round has not been established.

Recommendation of the use of dosage form is suitable for age.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What do

do when overdose? In chronic asthma studies, Montelukast is used at a dose of up to 200 mg/day for adult patients for 22 weeks and in short -term studies, 900 mg/day for patients for about 1 week without clinical serious side effects.

In case of overdose, common support measures may be used; As eliminating non -absorbing substances in the gastrointestinal tract, clinical monitoring and initial treatment, if necessary.

There are reports on acute overdose occurring in children with Montelukast at least 150 mg/day. Clinical and experimental findings in accordance with the summary description of safety in adults and older children. There is no unwanted effect that is reported in most cases of overdose. The most unwanted effect is thirsty, drowsy, dilated pupils, hyperactivity and abdominal pain.

It is unknown whether Montelukast is excluded by the abdominal separation or hemorrhage.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Do not drink twice as prescribed.

Side Effects

When using ASTHMATIN, you may experience unwanted effects (ADR).

Unknown frequency:

Blood and lymph: Increased bleeding trend.

The immune system: The hypersensitivity reactions include anaphylactic reactions, liver leukemia.

Psychiatric: Abnormal dreams such as nightmares, hallucinations, mental hyperactivity (including irritability, hyperactivity, anxiety such as aggressive and trembling), depression, insomnia, thinking and suicide behavior.

nerve: dizziness, drowsiness, abnormalities/reducing sensation, convulsions.

heart: Brush the chest drum.

Respiratory: Nasal bleeding, Churg syndrome - Strauss. digestive: diarrhea, dry mouth, indigestion, nausea, vomiting. Mile liver: Increases the concentration of transaminase in serum (ALT, AST), cholestatic hepatitis.

Skin and subcutaneous tissue: angioedema, bruises, urticaria, itching, rash, pink button.

muscle and connective tissue: joint pain, muscle pain including muscle spasm.

Common disorders: weakness/fatigue, discomfort, edema.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

ASTHMATIN drugs are contraindicated in cases of hypersensitivity to any component of the drug.

Be cautious when used

Do not use Montelukast to treat bronchospasm during acute asthma attacks. Patients should have appropriate emergency medicine. Can continue to use Montelukast in exacerbation of bronchial asthma.

While reducing the dose of corticosteroids spray slowly under medical monitoring, Montelukast should not be used instead of corticosteroids spray or oral form.

Do not use Montelukast as a single treatment for treatment and control of bronchial spasms due to exertion. Patients with severe asthma after exertion should continue the common treatment regime with the spray beta -shifting drug owner to prevent and can use the spray -shaped beta owner with short impact for emergency.

Patients sensitive to aspirin should avoid continuing to take aspirin or nonsteroidal anti -inflammatory drugs while taking Montelukast. Although Montelukast takes effect in improving respiratory function in people with asthma sensitivity to aspirin, it has not yet been shown to be removed from the bronchial contract caused by Aspirin and other nonsteroidal anti -inflammatory drugs in aspirin sensitive asthma patients.

Mental:

Mental manifestations have been reported in adults, adolescents and children to drink ASTHMATIN. The reports when using Montelukast include agitation, aggressive or hostile behavior, anxiety, depression, disorder, attention disorders, abnormal dreams, hallucinations, insomnia, discomfort, memory loss, restlessness, sleepwalking, thought and suicide behavior (including suicide), and trembling.

Patients and doctors should be wary of mental manifestations. Patients should be instructed to notify the doctor if these changes appear. Doctors should carefully assess the risks and benefits of continuing treatment with asthmatin if the above manifestations occur.

Incidental hypertension:

Patients with asthma treatment with ASTHMATIN may have a whole-body lymphoma, sometimes clinical manifestations of vasculitis in accordance with Churg-Strauss syndrome are often treated with systemic corticosteroids.

These manifestations are sometimes relevant to reduced oral corticosteroid treatment. Doctors should be alert to eosinophilia, vascular vascular, severe pulmonary symptoms, cardiovascular complications, and/or neurological diseases in patients.

In patients with urinary phenylceton:

Patients with urinary phenylceton should be notified as ASPHMATIN contains aspartam with 0.4 mg in Asthmatin 4 and 0.5 mg chewing tablets in ASTHMATIN 5 chewing tablets. Aspartam is a source of phenylalanin, which can be harmful to patients with patients with phenylketon (PKU), a rare genetic disorder causing phenylalanin appropriate waste.

The ability to drive and operate machinery

caused by Montelukast causes some unwanted effects on mental and nervousness. Some rare cases cause drowsiness, dizziness, so patients need to be cautious when driving and operating machinery.

Pregnancy

There are no complete and well -controlled studies in pregnant women. Because animal reproduction studies do not always predict to be met in humans, only Montelukast should be used if it is really necessary.

breastfeeding period

It is unknown whether Montelukast is excreted in breast milk or not. Because many drugs are excreted on breast milk, it is cautious when using Montelukast in breastfeeding mother.

Drug interaction

In Montelukast's recommended, clinical doses of clinical doses, there is no clinical important effect on the pharmacokinetics of the following drugs: Theophylllin, prednison, prednisolon, oral contraceptive (Ethinyl estradiol/Norethindron 35/1), Terfenadine, Digoxin and Digoxin and Digoxin and Digoxin and Digoxin and Digoxin and Digoxin Warfarin.

Do Montelukast is metabolized by CYP 3A4, 2C8 and 2C9, should be used carefully, especially in children, when used simultaneously with CYP 3A4, 2C8 and 2C9 induction substances such as phenytoin, phenobarbital and rifampicin.

Montelukast is a strong CYP 2C8 inhibitor. However, information from a clinical drug interactive study is related to Montelukast and Rosiglitazon (the exploration substrate represents the main metabolic drugs mainly by CYP 2C8) that has proven that Montelukast does not inhibit CYP 2C8 In Vivo. Therefore, Montelukast is unpredictable that changes significantly the metabolism of drugs metabolized by this enzyme (such as Paclitaxel, Rosiglitazon and Repaglinid).

Storage

Store in closed packaging, dry place. The temperature does not exceed 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.